Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Along with the improvement of living standard, the prevalence of Lower extremity arterial occlusive disease (LEAOD) is also increasing, which has become an important cause of lower extremity amputation and greatly affected the patients' life quality. Currently, percutaneous transluminal angioplasty (PTA), including balloon dilatation and stent implantation, has been regarded as the most widely applied and accepted treatment for LEAOD. The therapeutic effects of lower extremity interventional treatment, varied in different reports. It was reported that the therapeutic effects were influenced by some traditional risk factors, including age, gender, smoking, and so on. More risk factors are still unknown. The difference of therapeutic effects, the endpoint events were compared between interventional and conventional treatment group to analyze the effect of interventional treatment on LEAOD and explore its risk factors.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Interventional Therapy | Experimental | Percutaneous transluminal angioplasty. |
|
| Non-Interventional Therapy | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Percutaneous transluminal angioplasty | Procedure |
|
| Measure | Description | Time Frame |
|---|---|---|
| Ankle-brachial index | Change from baseline at 1 year(End of Trial) | |
| Mortality(%) | 1 year(End of Trial) | |
| Incidence of amputation(%) | 1 year(End of Trial) |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of major adverse cardiac events (MACE)(%) | 1 year(End of Trial) | |
| High-sensitive C reactive protein(mg/L) | Change from baseline at 1 year(End of Trial) | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yan Zhencheng, MD | Contact | 86-023-68757882 | zhenchengyan@sina.com | |
| Zhu Zhiming, MD, PhD | Contact | 86-23-68767881 | zhuzm@yahoo.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The third hospital affiliated to the Third Military Medical University | Recruiting | Chongqing | 400042 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36617729 | Derived | Zhang Q, Liu X, Li Q, Liu Y, He H, Wang K, Yan Z. Quantitative model for assessment of lower-extremity perfusion in patients with diabetes. Med Phys. 2023 May;50(5):3019-3026. doi: 10.1002/mp.16214. Epub 2023 Jan 16. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017130 | Angioplasty |
| ID | Term |
|---|---|
| D002404 | Catheterization |
| D013812 | Therapeutics |
| D057510 | Endovascular Procedures |
| D014656 | Vascular Surgical Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fasting plasma glucose(mmol/L) |
| Change from baseline at 1 year(End of Trial) |
| Blood pressure(mmHg) | Change from baseline at 1 year(End of Trial) |
| HbA1c(%) | Change from baseline at 1 year(End of Trial) |
| triglyceride(mmol/L) | Change from baseline at 1 year(End of Trial) |
| total cholesterol(mmol/L) | Change from baseline at 1 year(End of Trial) |
| LDL-c(mmol/L) | Change from baseline at 1 year(End of Trial) |
| HDL-c(mmol/L) | Change from baseline at 1 year(End of Trial) |
| The lower limb transcutaneous oxygen pressure(mmHg) | Change from baseline at 1 year(End of Trial) |
| D013504 |
| Cardiovascular Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
| D019060 | Minimally Invasive Surgical Procedures |
| D008919 | Investigative Techniques |